Aurobindo Q1 Profit Falls Despite EU Growth

  Published 11 months ago

Aurobindo Pharma's Q1 FY26 PBT dropped 8.8% YoY; Europe and ARV segments showed robust growth amid margin pressures.

  • European revenue grew 18% YoY to Rs 2,338 crore; US sales declined 1.9%, impacted by seasonal and destocking effects.
  • EBITDA margin shrank 102 bps YoY to 20.4%; API business revenue fell 16.1% while ARV business jumped 55.2%.
  • Interim dividend of Rs 4/share announced; record date set as 8 August, payout by 21 August 2025.

You might like these

India’s Exports Rise 6% in Q1 FY26

Astral Acquires Full Stake in Seal IT

Redington Elevates Apple's Distribution

HCLTech & UiPath Partner for AI-Powered Automation

Sapphire Foods Q2 FY26 Results Snapshot

Finolex Cables Shares Surge on Strong Outlook

Indegene Launches AI Writing Tool

News that matters the most ⚡